HBPCF.US Helix BioPharma Corp

Healthcare Biotechnology USA Stocks
0.7700 USD
Close of Nov 14, 2026
0.7700 1.73
Market cap
USD 58.8M
P/E
-
P/B
5.90x
ROE
-23.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jul 2026.

Is HBPCF.US undervalued?

Graham number

The Graham number of Helix BioPharma Corp cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Helix BioPharma Corp fundamental analysis

No fundamental analysis for Helix BioPharma Corp yet.

Helix BioPharma Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Helix BioPharma Corp

Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II…

Full company profile